Skip to main content
Fig. 1 | Trials

Fig. 1

From: A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

Fig. 1

Schematic representation of the study. In Part 1 patients with advanced disease will be enrolled to be administered carboplatin and olaparib in two 3-weekly cycles followed by olaparib monotherapy until dose limiting toxicity or progressive disease. The maximum tolerable dose will be determined

Back to article page

Trials

ISSN: 1745-6215